Antisense & RNAi Therapeutics Market Growth Through 2030 Creates New Strategic Opportunities
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Antisense & RNAi Therapeutics Market Value Expansion And Long-Term Growth Outlook
The antisense and RNAi therapeutics market has experienced significant expansion over the past few years. Its size is projected to increase from $1.93 billion in 2025 to $2.17 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.6%. This historical growth has been driven by the early application of antisense treatments, pioneering advances in RNAi research, improvements in oligonucleotide synthesis methods, a rising need for targeted therapies, and increased funding for biotechnology investigations.
The market for antisense and RNAi therapeutics is projected to experience rapid expansion over the coming years. Its value is anticipated to reach $3.53 billion by 2030, achieving a compound annual growth rate (CAGR) of 12.9%. During this forecast period, growth is fueled by progress in delivery technologies, the broadening of precision medicine, the incorporation of AI into drug discovery, a higher number of RNAi-focused clinical trials, and increased healthcare spending in developing regions. Key developments shaping this period feature targeted gene silencing, innovative delivery approaches, customized treatments, methods for stabilizing nucleic acids, and improvements in regulatory and clinical frameworks.
Download A Free Sample Report For Comprehensive Market Insights:
Antisense & RNAi Therapeutics Market Growth Drivers: What Factors Are Accelerating Expansion?
The increasing incidence of coronary artery diseases, neurodegenerative disorders, and infectious conditions is anticipated to boost demand within the antisense and RNAi therapeutics market. By repairing defective genes, gene suppression methods such as RNA interference and antisense oligonucleotides are applied to manage a range of neurodegenerative diseases. In January 2024, for example, the American Heart Association, a US-based organization, reported that the age-adjusted death rate from cardiovascular illnesses had risen to 233.3 per 100,000 individuals, marking a 4.0% increase compared to the prior year. Consequently, the escalating occurrence of multiple neurodegenerative and infectious ailments is expected to propel the expansion of the antisense and RNAi therapeutics market.
Antisense & RNAi Therapeutics Market Segment Outlook: Which Categories Are Expanding The Fastest?
The antisense & rnai therapeutics market covered in this report is segmented –
1) By Technology: RNA Interference, Antisense RNA
2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods
3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications
Subsegments:
1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics
2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides
Antisense & RNAi Therapeutics Market Trends: What Is Shaping Future Industry Growth?
Major players in the antisense and RNAi therapeutics space are adopting proactive strategies like collaborations and partnerships to maintain their competitive position. A strategic collaboration is defined as an arrangement where two or more firms join forces to pursue a shared objective. As an example, in January 2023, Orbit Discovery Limited, an American company specializing in peptide discovery services, formed a partnership with SanegeneBio Inc., a British organization focused on creating novel RNAi-based treatments. This alliance aims to identify tissue-specific delivery mechanisms for RNA therapeutics to achieve effective gene knockdown, with the ultimate goal of building a strong pipeline of advanced RNAi treatments. The agreement covers hit identification and cell-based internalization studies, and Sanegene retains the option to further develop any promising hits resulting from the screening process. This is achieved by tapping into Orbit’s proprietary technology, which accelerates the discovery of peptide leads. Orbit Discovery’s distinctive peptide display platform allows for the screening of extensive peptide libraries, significantly reducing the time needed to find appropriate peptide leads based on affinity and functional assays.
Antisense & RNAi Therapeutics Market Key Companies And Competitive Benchmarking
Major companies operating in the antisense & rnai therapeutics market are Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen Ilaç ve Saglik Ürünleri A.S., Egypt Otsuka Pharmaceutical
Access The Complete Antisense & RNAi Therapeutics Market Report:
Antisense & RNAi Therapeutics Market Regional Analysis And Leading Geography
North America was the largest region in the antisense & RNAi therapeutics market in 2025. The regions covered in the antisense & rnai therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
